
94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
ORIGINAL RESEARCH article
Front. Parasitol.
Sec. Antiparasitic Drugs and Drug Resistance
Volume 4 - 2025 | doi: 10.3389/fpara.2025.1523113
This article is part of the Research Topic Biomolecular Approaches to Trichomoniasis: Epidemiology, Diagnosis, and Treatment View all 3 articles
The final, formatted version of the article will be published soon.
You have multiple emails registered with Frontiers:
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Trichomonas vaginalis is a flagellated protozoan causing trichomoniasis, the most common non-viral sexually transmitted infection. It is associated with various complications, particularly in asymptomatic carriers. Another major cause of vaginitis is Candida albicans, a normal member of the vaginal microbiota, which causes vulvovaginal candidiasis when immune imbalances occur, leading to recurrent infections. Treatment-resistant strains of these pathogens pose a significant challenge. Lactobacillus crispatus, a dominant species in the vaginal microbiota, produces antimicrobial compounds that help protect the vaginal mucosa. This study establishes an in vitro co-culture of T. vaginalis, C. albicans, and L. crispatus to simulate the vaginal microenvironment at the site of infection. MRS medium was chosen for the co-culture, with initial cell densities determined as follows: T. vaginalis at 1.0 × 10⁶ trophozoites/mL (counted using a hemocytometer), 3.33 × 10⁴ CFU/mL for C. albicans, and either 5.53 × 10⁶ CFU/mL (for co-culture with the ATCC isolate) or 5.53 × 10⁷ CFU/mL (for co-culture with a fresh clinical isolate) for L. crispatus. The cell densities of C. albicans and L. crispatus were quantified as colony-forming units (CFU) on selective agar. The incubation period for co-culture, ensuring optimal growth of all microorganisms, was 24 hours. In co-culture, L. crispatus at both tested densities acidified the medium. The co-culture system demonstrated lower MIC values for metronidazole (50 µM in the ATCC isolate co-culture and 25 µM with the fresh clinical isolate) and lower MFC values for fluconazole (6.25 µM), compared to monocultures of T. vaginalis (100 µM) and C. albicans (12.50 µM). Furthermore, the triple co-culture increased the cytotoxicity to vaginal cell and erythrocytes for the ATCC isolate while significantly inhibited both biofilm formation and metabolic activity of C. albicans (by up to 92% and 90%, respectively), as well as its yeast-to-hyphae transition (by up to 70%). SEM analyses highlighted the morphological differences among T. vaginalis, C. albicans, and L. crispatus, including isolate-specific size variations in the protozoan. These findings suggest that this in vitro co-culture system is a valuable tool for evaluating the antimicrobial efficacy of novel compounds against vaginitis pathogens and for studying interactions within the vaginal microenvironment.
Keywords: Candida albicans, co-culture, Lactobacillus crispatus, Trichomonas vaginalis, vaginal microbiota, Vaginitis Excluído: Additionally, Excluído: Therefore, Justificado, Recuo: Primeira linha: 1 cm
Received: 05 Nov 2024; Accepted: 20 Mar 2025.
Copyright: © 2025 Cardoso, dos Santos, Menezes, Rigo and Tasca. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Tiana Tasca, Federal University of Rio Grande do Sul, Porto Alegre, 90040-060, Rio Grande do Sul, Brazil
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Research integrity at Frontiers
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.